Topical Collection

Particle Therapy: State-of-the-Art and Future Prospects

Message from the Collection Editors

Although particle therapy is perceived as a not sufficiently utilized, it is believed that its impact will be more substantial when the technology and clinical practices are optimized. Exciting technical advances have been reported, including ultra-high dose rates, biological optimizations, proton arcs, multi-ion therapy, superconducting gantry, improvements in beam-delivery efficiency, uncertainty reduction, and MR-guided proton therapy. On the other hand, the medical community eagerly awaits the data that demonstrate the clinical benefits of using particle therapy. This Topical Collection is devoted to the efforts in developing, improving, and using the most complex radiotherapy modality. We invite submissions on the following topics:

- Technical advances in proton and ion therapies;
- Clinical evidence in particle therapy;
- Clinical indications of particle therapy;
- Controversies in particle therapy;
- Novel applications of particle therapy to treat cancer and noncancerous tumors;
- Predictive outcome modeling for patients receiving particle therapy;
- Imaging for particle therapy—image guidance, uncertainty reduction, adaptive therapy, treatment effects.

Collection Editors

Dr. Chia-Ho Hua

Medical Physics Research, Department of Radiation Oncology, St. Jude Children's Research Hospital, 262 Danny Thomas, Memphis, TN 38105, USA

Dr. Matthew J. Krasin

Radiation Oncology, St. Jude Children's Research Hospital, 262 Danny Thomas, Memphis, TN 38105, USA

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/147422

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)